comprehensive -WSS

comprehensive

author：comprehensive 2025-09-29 09:30:04 - browse：68885

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Life sciences investors close nearly $6 billion in new funds

WSS

Analysis of telehealth claims data suggest service duplication

How neuroscience research could help beat back brain cancer

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Senate panel eyes new effort on drug shortages

Medicare proceeds with plan to claw back hospital funds

After Sarepta trial failure, Duchenne families brace for more debate

hotspot

comprehensive

focus

Hollywood unions extend contract negotiations for actors

Explaining an after

How one medical school became remarkably diverse

Lung cancer screening guidelines updated for cigarette smokers

Supreme Court strikes down use of affirmative action

Histogen: Failed biotech offers rare public look inside

Hepatitis C has a cure — but many Americans still lack access to it

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Walensky prepares to leave CDC — and Congress — behind

All of Us, NIH's precision medicine initiative, gets a big boost

entertainment

FDA rejects Alnylam's heart disease treatment over insufficient data

What is microchimerism and how does it affect maternal health?

Brain injuries and the importance of a second opinion

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Senate panel eyes new effort on drug shortages

Phenylephrine and the overlooked value of the placebo effect

focus

knowledge

Wikipedia

knowledge